CN Patent

CN110054662B — 一种固相合成Etelcalcetide的方法

Assigned to Chengdu Shengnuo Biopharm Co ltd · Expires 2021-03-02 · 5y expired

What this patent protects

本发明涉及医药合成领域，公开了一种固相合成Etelcalcetide的方法。本发明先合成Etelcalcetide主链肽序2‑7位的肽树脂，然后采用全保护的D‑半胱氨酸衍生物Ac‑D‑Cys[R1‑Cys‑OR2)]与所述肽树脂偶联，采用适宜的酸解液进行酸解，合成得到Etelcalcetide，最终所获得的Etelcalcetide具有较高的纯度和总收率。

USPTO Abstract

本发明涉及医药合成领域，公开了一种固相合成Etelcalcetide的方法。本发明先合成Etelcalcetide主链肽序2‑7位的肽树脂，然后采用全保护的D‑半胱氨酸衍生物Ac‑D‑Cys[R1‑Cys‑OR2)]与所述肽树脂偶联，采用适宜的酸解液进行酸解，合成得到Etelcalcetide，最终所获得的Etelcalcetide具有较高的纯度和总收率。

Drugs covered by this patent

Patent Metadata

Patent number
CN110054662B
Jurisdiction
CN
Classification
—
Expires
2021-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Shengnuo Biopharm Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.